Proteus mirabilis Hauser 拉丁名
(ATCC® BAA-2791™) 菌种编号
Reports Upon your purchase of this product, you will receive a report containing MIC values, a susceptibility profile, and the DNA sequence information for predicted annotated antibiotic resistance genes and 16S rRNA genes.
This report will be provided in multiple formats (.pdf, .txt, .xls, .zip).
Deposited As Proteus mirabilis
Strain Designations 菌种别名 927889
Application 用途 Drug discovery and development Development of molecular-based detection assays Development of updated sterility protocols
Isolation Urine
Isolation 分离源 Date 2013 Geographic Source Greece
Biosafety Level 生物安全等级 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Product Format 提供形式 frozen
Storage Conditions 保存方法 -80°C or colder
Preceptrol® no
Annotated Genes AAC(1) AAC(6')-Ib7 acrB APH3-Ia APH(3'')-Ib APH(3')-VIa APH(6)-Id cat catI CMY-4 macB mdtB mdtC mexB mexH mexI msbA TEM-1 tet(G) tet(J)
Type Strain 模式菌株 no
Antibiotic Resistance The depositor states that this strain is ESBL positive.
This has not been confirmed by ATCC.
MIC Range Susceptible Aztreonam: ≤4 μg/mL Cefepime: ≤2 μg/mL Doripenem: ≤1 μg/mL Meropenem: ≤1 μg/mL Piperacillin-tazobactam: ≤16/4 μg/mL Intermediate Fosfomycin: 128 μg/mL Resistant Amikacin: ≥64 μg/mL Amoxicillin-clavulanate: ≥32/16 μg/mL Ceftazidime: ≥16 μg/mL Ceftriaxone: ≥4 μg/mL Ciprofloxacin: ≥4 μg/mL Imipenem: ≥4 μg/mL Levofloxacin: ≥8 μg/mL Tetracycline: ≥16 μg/mL Trimethoprim-sulfamethoxazole: ≥4/76 μg/mL
Comments 注释 This strain is part of the ATCC® Clinical Isolates Collection. It is an extensively characterized antimicrobial-resistant clinical isolate with validated genotypic and phenotypic activity against a variety of drug classes.
This strain is provided with geographic source information; an NGS-assembled whole genome sequence, including annotated antibiotic resistance and rRNA genes; and an expanded level of susceptibility data with MIC test results.
Minimum inhibitory concentration (MIC) ranges for resistant, intermediate, and susceptible are based on criteria within the Clinical and Laboratory Standards Institute (CLSI) Performance Standards for Antimicrobial Susceptibility Testing, 26th Edition.
Predicted antimicrobial resistance gene sequence data are provided for informational purposes only and are based on open reading frames (ORFs) identified and annotated from contigs produced during NextGen Sequencing (NGS).
ATCC does not warrant that the entire predicted antimicrobial resistance gene is present within the sequence prepared for lot-specific reports.
Likewise, the information provided merely indicates that some portion of the sequence (whole or in part) is present based on analytical base pair alignment with known gene sequences.
Medium 培养基 ATCC® Medium 18: Trypticase Soy Agar/Broth
Growth Conditions 生长条件
Temperature 培养温度 : 37°C
Atmosphere 需氧情况 : Aerobic
Name of Depositor 寄存人 International Health Management Associates (IHMA), Inc.
Special Collection ATCC® Clinical
Isolates Collection
Chain of Custody 来源国家 ATCC <-- International Health Management Associates (IHMA), Inc.
Isolation 分离源 Urine Isolation Date 2013 Geographic Source Greece Patient Age 79 Patient Gender Male
References 参考文献 Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, 26th Edition. Wayne, PA. M100S, 2016.
